The discontinuation of immediate-release (IR) Adalat capsules and shortages of some other nifedipine products has led to supply issues in parts of the UK.
The 5mg and 10mg Adalat capsules were the only form of IR nifedipine available, as well as the only licensed treatment for Raynaud’s syndrome, until both strengths were discontinued by manufacturer Bayer.
Commenting on the discontinuation in June, the NHS Specialist Pharmacy Service (SPS)advised that patients with Raynuad’s syndrome on Adalat IR capsules could be switched to a similar dose of a modified-release (MR) nifedipine preparation.
Bayer discontinued its own MR nifedipine products – sold as Adalat Retard – last year, while it expects its three strengths of Adalat LA prolonged-release tablets to be out of stock until 2021.
Another supplier is in the process of launching a replacement IR preparation, which it expects to be available by early September.
Chiesi reported in May that its Adipine 10mg and 20mg MR tablets were experiencing a “bulk supply issue with raw ingredients and an increase in demand” following the discontinuation of Adalat.
No comments:
Post a Comment